MoonLake Immunotherapeutics
MLTX
10.77
-0.18
-1.64%
MoonLake Immunotherapeutics
US · MLTX
#3305 by market cap
Listed 2020
10.77
-0.18
-1.64%
Live - 5344 symbols - heartbeat 254s ago
· 2026-10-08 08:42
Pre-market
10.75
-0.19%
After-hours
10.96
+1.76%
- Market cap
- 916.60M
- P/E (TTM)i
- -2.80
- P/Bi
- 2.14
- EPSi
- -3.53
- Div yieldi
- 0.00%
- 52W posi
- 14%
Reader sentiment
Are you bullish or bearish on MLTX?
Anonymous reader poll. Unscientific, not investment advice.
Revenue annual, last 5 years
Key ratios & quality
- Enterprise valuei
- 597.96M
Income statement
| Line item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Gross profit | -- | -- | -- | -- | -- |
| Selling & admin expenses | -- | 23.01M | 22.32M | 30.32M | 41.97M |
| Research & development | -- | 42.05M | 31.80M | 112.77M | 202.86M |
| Operating profit | -- | -65.06M | -54.12M | -143.09M | -244.83M |
| Pretax profit | -- | -64.47M | -43.99M | -120.96M | -229.71M |
| Tax | -- | 36.37K | 94.00K | 282.00K | 611.00K |
| Net profit | -- | -64.51M | -44.08M | -121.24M | -230.32M |
| Basic EPS | -- | -2 | -1 | -2 | -4 |
| Diluted EPS | -- | -1.70 | -0.73 | -1.89 | -3.53 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- | -- |
| Gross profit | -- | -- | -- | -- | -- | -- |
| Selling & admin expenses | 11.03M | 10.94M | 10.80M | 9.21M | 15.51M | 11.44M |
| Research & development | 36.46M | 49.76M | 60.64M | 56.01M | 54.52M | 50.22M |
| Operating profit | -47.49M | -60.70M | -71.43M | -65.22M | -70.02M | -61.66M |
| Pretax profit | -40.41M | -55.96M | -70.58M | -62.77M | -69.09M | -61.72M |
| Tax | 153.00K | 95.00K | 115.00K | 248.00K | 622.00K | 90.00K |
| Net profit | -40.56M | -56.05M | -70.69M | -63.02M | -69.71M | -61.81M |
| Basic EPS | -1 | -1 | -1 | -1 | -1 | -1 |
| Diluted EPS | -0.63 | -0.87 | -1.10 | -0.92 | -0.98 | -0.84 |
Balance sheet
| Line item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total current assets | 9.64M | 76.51M | 514.17M | 474.29M | 421.69M |
| Cash & ST investments | 8.04M | 72.11M | 511.01M | 448.03M | 393.97M |
| Inventory | -- | -- | -- | -- | -- |
| Total assets | 9.68M | 76.84M | 526.54M | 477.93M | 424.43M |
| Total current liabilities | 21.09M | 7.67M | 9.97M | 22.46M | 45.48M |
| Short-term debt | 15.00M | 153.63K | 1.20M | 1.37M | 1.23M |
| Long-term debt | -- | -- | -- | -- | 74.10M |
| Total liabilities | 21,327,461.00 | 8,076,603.00 | 13,049,096.00 | 24,542,000.00 | 119,952,000.00 |
| Total equity | -11.65M | 68.77M | 513.49M | 453.39M | 304.48M |
| Retained earnings | -53.64M | -80.65M | -116.66M | -235.59M | -462.91M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 506.26M | 455.48M | 411.22M | 421.69M | 396.64M | 570.04M |
| Cash & ST investments | 480.13M | 425.08M | 380.48M | 393.97M | 357.92M | 537.03M |
| Inventory | -- | -- | -- | -- | -- | -- |
| Total assets | 511.26M | 460.10M | 414.34M | 424.43M | 400.37M | 573.95M |
| Total current liabilities | 23.98M | 27.36M | 48.37M | 45.48M | 46.11M | 45.39M |
| Short-term debt | 1.43M | 1.55M | 1.50M | 1.23M | 920.00K | 1.25M |
| Long-term debt | 73.02M | 73.38M | 73.74M | 74.10M | 99.02M | 99.51M |
| Total liabilities | 98,681,000.00 | 102,152,000.00 | 123,144,000.00 | 119,952,000.00 | 146,350,000.00 | 145,752,000.00 |
| Total equity | 412.58M | 357.94M | 291.19M | 304.48M | 254.02M | 428.20M |
| Retained earnings | -275.54M | -330.76M | -400.49M | -462.91M | -532.62M | -594.42M |
Cash flow
| Line item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Operating cash flow | -- | -55.89M | -42.78M | -116.59M | -196.01M |
| Depreciation & amortization | -- | 164.78K | 370.00K | 1.39M | 2.62M |
| Free cash flow | -- | -55.91M | -43.06M | -117.11M | -196.04M |
| Dividends paid | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | -- | 0 | 482.45M | 52.54M | 72.40M |
| Ending cash balance | -- | 39.51M | 451.17M | 180.43M | 334.52M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | -38.14M | -54.53M | -44.54M | -58.79M | -66.29M | -55.56M |
| Depreciation & amortization | 378.00K | 742.00K | 745.00K | 751.00K | 845.00K | 896.00K |
| Free cash flow | -38.18M | -54.53M | -44.54M | -58.79M | -66.29M | -55.56M |
| Dividends paid | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | 0 | 0 | 0 | 72.40M | 6.01M | 234.07M |
| Ending cash balance | 271.57M | 306.68M | 350.74M | 334.52M | 298.49M | 477.91M |
Returns & efficiency
| Line item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| ROE %i | -- | -268.81 | -13.22 | -25.24 | -60.51 |
| ROA %i | -- | -115.51 | -11.94 | -23.68 | -50.38 |
| ROIC %i | -- | -190.04 | -13.13 | -25.06 | -53.19 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- |
| EBIT margin %i | -- | -- | -- | -- | -- |
| FCF / sales %i | -- | -- | -- | -- | -- |
| Current ratioi | 0.46 | 9.98 | 51.59 | 21.11 | 9.27 |
| Quick ratioi | 0.39 | 9.44 | 51.38 | 20.07 | 8.77 |
| Debt / assetsi | 154.92 | 0.37 | 0.70 | 0.59 | 17.84 |
| LT debt / equityi | -- | 0.26 | 0.50 | 0.33 | 24.46 |
| Interest coveragei | -- | -- | -- | -- | -30.69 |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | 0.00 |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | -30.57 | -40.29 | -54.17 | -60.51 | -77.72 | -67.44 |
| ROA %i | -27.01 | -35.06 | -45.14 | -50.38 | -56.40 | -51.00 |
| ROIC %i | -28.21 | -36.95 | -49.15 | -53.19 | -60.00 | -53.71 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | -- | -- | -- | -- | -- | -- |
| FCF / sales %i | -- | -- | -- | -- | -- | -- |
| Current ratioi | 21.11 | 16.65 | 8.50 | 9.27 | 8.60 | 12.56 |
| Quick ratioi | 20.15 | 15.66 | 7.95 | 8.77 | 7.89 | 11.98 |
| Debt / assetsi | 14.79 | 16.47 | 18.28 | 17.84 | 25.18 | 17.69 |
| LT debt / equityi | 18.20 | 20.98 | 25.69 | 24.46 | 39.32 | 23.42 |
| Interest coveragei | -- | -- | -- | -30.69 | -26.20 | -25.17 |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
Quote time 2026-10-08 08:42:36 · For reference only, not investment advice and not tailored to your situation.